Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AC Immune S.A.
(NQ:
ACIU
)
2.370
+0.080 (+3.49%)
Streaming Delayed Price
Updated: 9:42 AM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AC Immune S.A.
< Previous
1
2
Next >
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
March 14, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
February 22, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
January 22, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
January 03, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Pricing of Underwritten Offering of Common Shares
December 15, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
December 15, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
December 01, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
November 07, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 03, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
November 02, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
October 27, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
October 17, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
October 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
September 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 04, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
July 28, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune SA Appoints New Chief Medical Officer
July 26, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
July 03, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
June 27, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Holds Annual General Meeting of Shareholders
June 23, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
April 28, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
April 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
March 20, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
March 16, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
March 08, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
February 07, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the SVB Securities Global Biopharma Conference
February 02, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
January 26, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
January 18, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
November 30, 2022
From
AC Immune SA
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.